Rhodium-Catalyzed Asymmetric Conjugate Additions of Boronic Acids to Enones Using DIPHONANE: A Novel Chiral Bisphosphine Ligand

Koen Vandyck, Bavo Matthys, Mario Willen, Koen Robeyns,† Luc Van Meervelt,† and Johan Van der Eycken*

*Laboratory for Organic and Bioorganic Synthesis, Department of Organic Chemistry, Ghent Uni*V*ersity, Krijgslaan 281 (S.4), B-9000 Gent, Belgium*

*johan.*V*andereycken@ugent.be*

Received September 20, 2005 (Revised Manuscript Received December 6, 2005)

ABSTRACT

The synthesis of a novel enantiopure C2-symmetric bisphosphine, DIPHONANE, was accomplished starting from 2,5-norbornadione, utilizing (R,R)- and/or (S,S)-(2,3-O-di[(phenylamino)carbonyl]tartaric acid for the resolution of an intermediate phosphineoxide. The application of this ligand in the rhodium-catalyzed asymmetric conjugate addition of boronic acids to cyclic enones provides the 1,4-addition products in good yields (69−**98%) and high ee's (78**−**95% ee). A byproduct arising from a consecutive 1,4-addition and 1,2-addition was also observed.**

The 1,4-addition of aryl or alkenyl groups to electrondeficient double bonds constitutes an interesting approach for C-C bond formation.¹ Therefore, the asymmetric rhodium-catalyzed 1,4-addition to α , β -unsaturated enones has recently received a lot of attention applying various ligands such as biaryl bisphosphines,² phosphoramidites, $3a$,b BINOLbased diphosphonites,^{3c} amidomonophosphines,^{3d} N-heterocyclic carbenes,^{3e} ferrocenyl-based bisphosphines,^{2c} a P-chiral phosphine, $3f$ and dienes. $3g-k$ Some other bisphosphine ligands, although efficient in the Rh(I)-catalyzed hydrogenation, fail

ORGANIC LETTERS

2006 Vol. 8, No. 3 ³⁶³-**³⁶⁶**

[†] Biomolecular Architecture, Department of Chemistry, K. U. Leuven, Celestijnenlaan 200F, B-3001 Leuven (Heverlee), Belgium.

⁽¹⁾ For a review on rhodium-catalyzed asymmetric 1,4-addition and $C-C$ bond formation, respectively, see: (a) Hayashi, T.; Yamasaki, K. *Chem. Re*V*.* **²⁰⁰³**, *¹⁰³*, 2829-2844. (b) Fagnou, K.; Lautens, M. *Chem. Re*V*.* **²⁰⁰³**,

¹⁰³, 169-196. (2) (a) Takaya, Y.; Ogasawara, M.; Hayashi, T.; Sakai, M.; Miyaura, N. *J. Am. Chem. Soc.* **¹⁹⁹⁸**, *¹²⁰*, 5579-5580. (b) Amengual, R.; Michelet, V.; Genêt, J.-P. *Synlett* **2002**, 1791-1794. (c) Pucheault, M.; Darses, S.; Genêt J -P *Eur J. Org Chem* 2002, 3552-3557 (d) Shi O · Xu L · Li Genêt, J.-P. *Eur. J. Org. Chem.* **2002**, 3552–3557. (d) Shi, Q.; Xu, L.; Li, X.; Jia, X.; Wang, R.; Au-Yeung, T. T.-L.; Chan, A. S. C.; Hayashi, T.; Cao, R.; Hong, M. *Tetrahedron Lett.* **²⁰⁰³**, *⁴⁴*, 6505-6508. (e) Madec, J.; Michaud, G.; Genêt, J.-P.; Marinetti, A. *Tetrahedron: Asymmetry* 2004, *15*, 2253–2261. (f) Yuan, W.-Y.; Cun, L.-F.; Gong, L.-Z. Mi, A.-Q.; Jiang, *15*, 2253–2261. (f) Yuan, W.-Y.; Cun, L.-F.; Gong, L.-Z. Mi, A.-Q.; Jiang, Y.-Z. Tetrahedron Lett. 2005. 46. 509–512. (g) Ogasawara, M.: Ngo, H. Y.-Z. *Tetrahedron Lett.* **²⁰⁰⁵**, *⁴⁶*, 509-512. (g) Ogasawara, M.; Ngo, H. L.; Sakamoto, T.; Takahashi, T.; Lin, W. *Org. Lett.* **²⁰⁰⁵**, *⁷*, 2881-2884.

^{(3) (}a) Boiteau, J.-G. Minnaard, A. J, Feringa, B. L. *J. Org. Chem.* **2003**, *⁶⁸*, 9481-9484. (b) Iguchi, Y.; Itooka, R.; Miyaura, N. *Synlett* **²⁰⁰³**, 1040- 1042. (c) Reetz, M. T.; Moulin, D.; Gosberg, A. *Org. Lett.* **²⁰⁰¹**, *³*, 4083- 4085. (d) Kuriyama, M.; Nagai, K.; Yamada, K.-I.; Miwa, Y.; Taga, T.; Tomioka, K. J. Am. Chem. Soc. 2002, 124, 8932-8939. (e) Ma, Y.; Song, Tomioka, K. *J. Am. Chem. Soc.* **²⁰⁰²**, *¹²⁴*, 8932-8939. (e) Ma, Y.; Song, S.; Ma, C.; Sun, Z.; Chai, Q.; Andrus, M. B. *Angew Chem., Int. Ed.* **2003**, *⁴²*, 5871-5874. (f) Imamoto, T.; Sugita, K.; Yoshida, K. *J. Am. Chem. Soc.* **²⁰⁰⁵**, *¹²⁷*, 11934-11935. (g) Defieber, C.; Paquin, J.-F.; Serna, S.; Carreira, E. M. *Org. Lett.* **²⁰⁰⁴**, *⁶*, 3873-3876. (h) Hayashi, T.; Ueyama, K.; Tokunaga, N.; Yoshida, K*. J. Am. Chem. Soc.* **²⁰⁰³**, *¹²⁵*, 11508-11509. (i) Otomaru, Y.; Kina, A.; Shintani, R.; Hayashi, T. *Tetrahedron: Asymmetry* **²⁰⁰⁵**, *¹⁶*, 1673-1679. (j) Otomaru, Y.; Okamoto, K.; Shintani, R.; Hayashi, T. *J. Org. Chem.* **²⁰⁰⁵**, *⁷⁰*, 2503-2508. (k) Lang, F.; Breher, F.; Stein, D.; Grützmacher, H. *Organometallics* **2005**, 24, 2997-3007. For some recent results on 1,4-additions to other α , β -unsaturated systems, see: (l) Paquin, J. F.; Defieber, C.; Stephenson, C. R. J.; Carreira, E. M. *J. Am. Chem. Soc.* **2005**, *127*, **10850**-10851 for enals. (m) Paquin, J. F.; Stephenson, C. R. J.; Defieber, C.; Carreira, E. M. *Org. Lett.* **2005**, 7, 3821-Stephenson, C. R. J.; Defieber, C.; Carreira, E. M. *Org. Lett.* **²⁰⁰⁵**, *⁷*, 3821- 3824 for acrylic esters. (n) Shintani, R.; Duan, W. L.; Nagano, T.; Okada, A.; Hayashi, T. *Angew. Chem., Int. Ed.* **²⁰⁰⁵**, *⁴⁴*, 4611-4614 for maleimides. (o) Shintani, R.; Kimura, T.; Hayashi, T. *Chem. Commun*. **2005**, *²⁵*, 3213-3214 for Weinreb amides. (p) Jagt, R. B. C.; de Vries, J. G.; Feringa, B. L.; Minnaard, A. J. *Org. Lett.* **²⁰⁰⁵**, *⁷*, 2433-2435 for 2,3 dihydro-4-pyridones. (q) Chen, G.; Tokunaga, N.; Hayashi, T. *Org. Lett.* **²⁰⁰⁵**, *7,* ²²⁸⁵-2288 and references therein for coumarins.

to induce high reactivity and/or selectivity in the rhodiumcatalyzed 1,4-addition to α , β -unsaturated enones.^{1,2a,c} Within our interest for the design of new ligand architectures⁴ and stimulated by the synthesis of $DIANANE⁵$ (Figure 1), we

wish to present our results concerning the synthesis and application of a novel C_2 -symmetric bisphosphine, DIPHO-NANE.

Our approach started with the known 2,5-norbornadione (\pm) -1⁶ (Scheme 1). Dienolization/alkylation of this interme-

diate is usually addressed in two separate steps, $3h,j,7$ but nevertheless the dienolization with KHMDS followed by treatment with $PhNTf_2$ gave a satisfactory yield of the bistriflate (\pm) -2. Pd (0) -catalyzed coupling of 2 with HPPh₂ and subsequent oxidation resulted in the racemic vinylic bisphosphineoxide (\pm) -3^{8,9} This intermediate was preferred
over its phosphino-borane complex because it allows resoluover its phosphino-borane complex because it allows resolution by applying the hydrogen bonding capacity of the phosphineoxide and BH3-protected phosphines tend to act as a catalyst poison for heterogeneous hydrogenation.10 Hydrogenation with Pd on charcoal (10 w/w %) resulted stereoselectively in *endo*-bisphosphine-oxide (\pm) -4.

The bis-*endo* configuration of (\pm) -4 could be deduced from the ${}^{3}J_{\text{PC}}$ coupling in the ${}^{31}P$ NMR spectrum of P with C₇ being 15.2 Hz (expected *endo* = $12-16.8$ Hz, $exo \approx 0$ Hz).11 Nevertheless, resolutions applying commercial (*R*,*R*)- (-)-di-*O,O*-benzoyltartaric acid (DBTA) **⁷**, *^R*-(-)-mandelic acid **9**, or $(1R)$ -(-)-camphorsulfonic acid (CSA) **10** (Figure 2) were unsuccessful. Fortunately, when (*R*,*R*)-(2,3-di-

Figure 2. Chiral acids tested for the resolution of (\pm) -4.

[(phenylamino)carbonyl]tartaric acid **8** or its enantiomer was applied (both obtained in three steps from the corresponding tartaric acid¹²), bis-phosphineoxide (\pm) -4 was resolved with high enantiomeric excess (>98% ee), as determined by HPLC analysis with a chiral stationary phase column (Chiralpak AD-H). In this way, enantiomerically pure (2*S*,5*S*)-**4** could be obtained in 35% yield in two steps from (\pm) -3. Reduction of the phosphineoxide $(HSi(OEt)_{3}$, $Ti(OiPr)_4$ ¹³ was followed by reprotection with BH₃ to ensure easy purification of the phosphine precursor, resulting in the isolation of 5. Again, the ${}^{3}J_{\text{PC}}$ coupling with C₇ appeared to be large (12.8 Hz), proving that no epimerization had occurred. The absolute configuration of **5**, being (+)-(1*S*,2*S*,4*S*,5*S*) was established by single-crystal X-ray diffraction (Figure 3).⁸ By refluxing the phosphine-borane in EtOH, an efficient procedure recently applied in our group for mild deprotection of phosphines,14 DIPHONANE **6** was obtained.

The efficiency of our new ligand was tested in the rhodium-catalyzed 1,4-addition of arylboronic acids to enones (Table 1). $1-3$ We first examined the addition of phenylboronic acid **12a** to cyclohexenone **11A**. In accordance

^{(4) (}a) Vandyck, K.; Matthys, B.; Van der Eycken, J. *Tetrahedron. Lett.* **²⁰⁰⁵**, *⁴⁶*, 75-78. (b) Kuppens T.; Vandyck K.; Van der Eycken J.; Herrebout W.; van der Veken, B. J.; Bultinck P. *J. Org. Chem.* **2005**, *70,* ⁹¹⁰³-9114. (c) De Coster, G.; Vandyck, K.; Van der Eycken, E.; Van der Eycken, J.; Elseviers, M.; Röper, H. *Tetrahedron: Asymmetry* 2002, 13, ¹⁶⁷³-1679.

^{(5) (}a) Berkessel, A.; Schröder, M.; Sklorz, C. A.; Tabanella, S.; Vogl, N.; Lex, J.; Neudörfl, J. M. *J. Org. Chem.* **2004**, 69, 3050-3056. (b) Berkessel, A.; Menche, D.; Sklorz, C. A.; Schröder, M.; Paterson I. Angew.

Chem., Int. Ed. **²⁰⁰³**, *⁴²*, 1032-1035. (6) Hawkins, R. T.; Hsu, R. S.; Wood, S. G. *J. Org. Chem.* **1978**, *43*, ⁴⁶⁴⁸-4650.

⁽⁷⁾ Smith, B. T.; Wendt, J. A.; Aube, J. *Org. Lett.* **²⁰⁰²**, *⁴*, 2577-2579. (8) See Supporting Information for X-ray diffraction structure.

⁽⁹⁾ Gilbertson, S. R.; Fu, Z.; Starkey, G. W. *Tetrahedron Lett.* **1999**, *⁴⁰*, 8509-8512.

^{(10) (}a) Boerner, A.; Ward, J.; Ruth, W.; Holz, J.; Kless, A.; Heller, D.; Kagan, H. B. *Tetrahedron* **¹⁹⁹⁴**, *⁵⁰*, 10419-10430. (b) Vandyck, K.; Van der Eycken, J. Unpublished results.
(11) Maffei, M.; Buono, G. New J. Chem. 1988, 12, 923–930.

⁽¹¹⁾ Maffei, M.; Buono, G. *New J. Chem.* **¹⁹⁸⁸**, *¹²*, 923-930. (12) (a) Cereghetti, M.; Rageot, A. European Patent 511 558, 1992. (b) Cereghetti, M.; Schmid, R.; Schönholzer, P.; Rageot, A. *Tetrahedron Lett.* **¹⁹⁹⁶**, *³⁷*, 5343-5346. (c) Chen, Y.-X.; Li, Y.-M.; Lam, K.-H.; Chan, A. S. C. *Chin. J. Chem.* **²⁰⁰¹**, *¹⁹*, 794-799.

⁽¹³⁾ Coumbe, T.; Lawrence, J. N.; Muhammad, F. *Tetrahedron Lett.* **¹⁹⁹⁴**, *³⁵*, 625-628.

⁽¹⁴⁾ Although addition of DABCO accelerated the reaction, it was not crucial to obtain full conversion. For deprotection with EtOH, see: (a) Moulin, D.; Bago, S.; Bauduin, C.; Darcel, C.; Jugé, S. *Tetrahedron: Asymmetry* **²⁰⁰⁰**, *¹¹*, 3939-3956. (b) Vervecken, E.; Van der Eycken, J. To be submitted.

Figure 3. X-ray crystal structure of (2*S*,5*S*)-**5**.

with earlier findings,¹⁵ we observed that the generation of the catalyst from $[RhCl(C₂H₄)₂]$ in the presence of KOH and (*S*,*S*)-DIPHONANE (entry 1) resulted in a more active catalyst than in the case of (*S*,*S*)-DIPHONANE with $Rh (acac)(C_2H_4)_2$ (entries 2 and 3), whereas the 1,4-addition product was produced with comparable enantiomeric excess (85% and 86% ee, respectively). The use of 3 mol % of catalyst (entry 4) instead of 1 mol % (entry 1) resulted in an equal enantiomeric excess (85%). The $[RhCl(C₂H₄)₂]$ ₂/KOH/ DIPHONANE system allowed lowering the reaction tem-

^a Standard conditions [RhCl(C2H4)2]2/DIPHONANE/cyclohexenone 0.5/1.1/100, ∼0.35 M **11A**, 1.5 equiv KOH, 5 equiv PhB(OH)2. *^b* Isolated as a mixture with **14Aa**. *^c* Determined by HPLC analysis with a chiral stationary phase column (Chiralcel AD-H). *^d* Determined from 1H NMR ratio with (*R*)-**13Aa** based on **11A**, enantiomeric excess determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H). e 1% Rh(acac)(C₂H₄)₂ was used as catalyst precursor without the addition of base. f 1.5% [RhCl(C₂H₄)₂]₂ was used. ^{*g*} 1.5 equiv NEt₃ was applied as a base. *^h* 0.91 M **11A**, 2 equiv PhB(OH)2. *ⁱ* ∼95% de.

14*^h* 45 dioxane/H2O 10/1 19 50 91 32 (89)*ⁱ*

perature to 50 °C (entries 5 and 6), affording the product with an enantiomeric excess of 91%. Changing the base from KOH to NEt₃ (entry 7) or changing the solvent (entries $8-13$) did not lead to better results.

As a byproduct, resulting from the asymmetric 1,4-addition and a consecutive 1,2-addition, (1*R*,3*R*)-1,3-diphenyl-cyclohexanol **14Aa** could be isolated.16 The Rh(I)-catalyzed 1,2 arylation of ketones is usually limited to strained ketones as acceptor or to intramolecular additions, whereas arylation of aldehydes or aldimines has been described to a much larger extent.^{1,17} The 1,2-addition showed a high level of diastereoselectivity (95% de, entry 14), whereas the resulting product **14Aa** showed a comparable enantiomeric excess as the initial 1,4-adduct **13Aa** (entries 5, 6, and 14). At higher concentration (0.91 M **11A**) **14Aa** was formed in up to 32%, applying only 2 equiv **12a** at 45 °C.

Extending the Rh(I)/DIPHONANE-catalyzed addition to a variety of boronic acids **12a**-**^f** and a range of acceptors **11A**-**^E** (Table 2) revealed high selectivity in the addition of $4-CF_3-Ph$ (12b) and 1-naphthyl boronic acid (12d) to cyclohexenone (**11A**, 92% ee, entry 1, and 95% ee, entry 3, respectively). The hindered *o*-tolyl boronic acid (**12e**) gave

a Isolated yield. $nc = no$ conversion. *b* Determined by HPLC analysis with a chiral stationary phase column (Chiralpak AD-H or Chiralcel OD-H). ^{*c*} 3% Rh(acac)(CH₂CH₂)₂, 3.3% (2*S*,5*S*)-6, dioxane/H₂O 10/1, 100 °C.

a lower selectivity and yield (69% yield, 78% ee, entry 4), whereas no reaction was observed for 2,6-dimethylphenyl boronic acid (**12f**, entry *5*). A lower selectivity also was observed with the electron-rich 4-MeO-Ph boronic acid (79% ee, 73% yield, entry 2).

The Rh(I)/DIPHONANE-catalyzed addition was also applied to cyclopentenone **11B** and cycloheptenone **11C** as acceptors. The addition to **11B** resulted in the phenyl adduct **13Ba** with good selectivity and excellent yield (entry 6, 83% ee, 96% yield). Addition to **11C** with both phenylboronic acid (**12a**) and 1-naphthylboronic acid (**12d**) resulted in the corresponding 1,4-adducts with high yield and good stereoselectivity (**13Ca**, entry 7, 98% yield, 86% ee and **13Cd**, entry 8, 96% yield and 95% ee, respectively.)

No reactivity was observed in the addition of **12a** to coumarin **11D** (entry 9).^{3q} Although the catalyst showed good reactivity in the addition of **12a** to the linear enone **11E** (92% yield, entry 10), the enantioselectivity dropped remarkably (31% ee) Noteworthy is the fact that 1,2-addition was only observed in minor amounts (<3%) in the case of **13Ad** and **13Ab.**

In conclusion, the Rh(I) complex derived from the new bisdiphenylphosphine DIPHONANE catalyses the asymmetric 1,4-addition of boronic acids to enones with ee's up to 95% ee. The intermediate **2** should allow elaboration of a broader range of 2,5-norbornane bisphosphines, both *C*2 and *C*1-symmetric.

Acknowledgment. The authors gratefully acknowledge financial support by Ghent University. K.V. is a Research Assistant of the Research Foundation-Flanders (F.W.O.- Vlaanderen).

Supporting Information Available: Experimental procedures and characterization of compounds **²**-**6**, **14Aa** and its epimer **15Aa**, and **13Cd**. X-ray crystal structure of (\pm) -3 and (1*S*,2*S*,4*S*,5*S*)-**5** in CIF format. This material is available free of charge via the Internet at http://pubs.acs.org.

OL0522788

⁽¹⁵⁾ Hayashi, T.; Takahashi, M.; Takaya, Y.; Ogasawara, M. *J. Am. Chem. Soc.* **²⁰⁰²**, *¹²⁴*, 5052-5058.

⁽¹⁶⁾ For the assignment of the configuration, see Supporting Information. (17) Intermolecular Rh-catalyzed 1,2-addition of arylboronic acids to cyclobutanone: (a) Matsuda, T.; Makino, M.; Murakami, M. *Org. Lett.* **²⁰⁰⁴**, *⁶*, 1257-1259. (b) Matsuda, T.; Makino, M.; Murakami, M. *Bull. Chem. Soc. Jpn.* **²⁰⁰⁵**, *⁷⁸*, 1528-1533. Intramolecular Rh-catalyzed 1,2 addition to ketones: (c) Takewasa, A.; Yamoguchi, K.; Ohmuna, T.; Yamamoto, Y.; Miyaura, N. *Synlett* **²⁰⁰²**, 1733-1735. (d) Miura, T.; Shimada, M.; Murakami, M. *Synlett* **²⁰⁰⁵**, 667-669. (e) Shintani, R.; Okamoto, K.; Otomaru, Y.; Ueyama, K.; Hayashi, T. *J. Am. Chem. Soc.* **²⁰⁰⁵**, *¹²⁷*, 54-55. (f) Matsuda, T.; Makino, M.; Murakami, M. *Angew. Chem., Int. Ed.* **²⁰⁰⁵**, *⁴⁴*, 4608-4611. Rh-catalyzed trimethylphenylstannane addition to cyclohexanone: (g) Oi, S.; Moro, M.; Fukuhara, H.; Kawanishi, T.; Inoue, Y. *Tetrahedron* **²⁰⁰³**, *⁵⁹*, 4351-4361.